Cetera Advisor Networks LLC Buys 5,245 Shares of Stryker Co. (NYSE:SYK)

Cetera Advisor Networks LLC grew its stake in shares of Stryker Co. (NYSE:SYKGet Rating) by 45.4% during the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 16,798 shares of the medical technology company’s stock after buying an additional 5,245 shares during the quarter. Cetera Advisor Networks LLC’s holdings in Stryker were worth $3,342,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Carolinas Wealth Consulting LLC grew its stake in shares of Stryker by 3.0% during the first quarter. Carolinas Wealth Consulting LLC now owns 1,533 shares of the medical technology company’s stock worth $411,000 after buying an additional 45 shares during the last quarter. D.B. Root & Company LLC grew its stake in shares of Stryker by 1.6% during the first quarter. D.B. Root & Company LLC now owns 2,969 shares of the medical technology company’s stock worth $793,000 after buying an additional 48 shares during the last quarter. EverSource Wealth Advisors LLC grew its stake in shares of Stryker by 41.4% during the first quarter. EverSource Wealth Advisors LLC now owns 164 shares of the medical technology company’s stock worth $44,000 after buying an additional 48 shares during the last quarter. Wintrust Investments LLC grew its stake in shares of Stryker by 6.7% during the first quarter. Wintrust Investments LLC now owns 811 shares of the medical technology company’s stock worth $217,000 after buying an additional 51 shares during the last quarter. Finally, Donaldson Capital Management LLC grew its stake in shares of Stryker by 2.3% in the second quarter. Donaldson Capital Management LLC now owns 2,226 shares of the medical technology company’s stock worth $443,000 after purchasing an additional 51 shares during the last quarter. Institutional investors own 76.44% of the company’s stock.

Stryker Stock Up 1.7 %

Shares of NYSE:SYK opened at $230.29 on Thursday. The business’s 50 day simple moving average is $215.86 and its two-hundred day simple moving average is $214.51. The firm has a market cap of $87.15 billion, a P/E ratio of 35.81, a PEG ratio of 2.80 and a beta of 0.99. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.19 and a current ratio of 2.04. Stryker Co. has a 52-week low of $188.84 and a 52-week high of $280.43.

Stryker (NYSE:SYKGet Rating) last posted its earnings results on Monday, October 31st. The medical technology company reported $2.12 earnings per share for the quarter, missing analysts’ consensus estimates of $2.23 by ($0.11). Stryker had a net margin of 13.69% and a return on equity of 22.27%. The company had revenue of $4.48 billion during the quarter, compared to the consensus estimate of $4.46 billion. During the same quarter in the prior year, the business earned $2.20 EPS. The firm’s revenue for the quarter was up 7.7% compared to the same quarter last year. As a group, research analysts forecast that Stryker Co. will post 9.17 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts recently weighed in on SYK shares. Piper Sandler reduced their price objective on shares of Stryker from $260.00 to $250.00 in a research note on Monday, October 10th. Canaccord Genuity Group cut shares of Stryker from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $225.00 to $220.00 in a research note on Tuesday, November 1st. Truist Financial boosted their price objective on shares of Stryker to $230.00 in a research note on Friday, November 4th. Robert W. Baird dropped their target price on shares of Stryker from $297.00 to $240.00 and set an “outperform” rating on the stock in a report on Wednesday, July 27th. Finally, Citigroup dropped their target price on shares of Stryker from $255.00 to $246.00 in a report on Wednesday, October 5th. Six research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. Based on data from MarketBeat.com, Stryker currently has an average rating of “Moderate Buy” and an average price target of $247.74.

Insider Activity

In other news, VP M Kathryn Fink sold 340 shares of the firm’s stock in a transaction that occurred on Wednesday, November 2nd. The stock was sold at an average price of $219.68, for a total value of $74,691.20. Following the transaction, the vice president now owns 12,774 shares in the company, valued at $2,806,192.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, VP M Kathryn Fink sold 340 shares of the stock in a transaction that occurred on Wednesday, November 2nd. The stock was sold at an average price of $219.68, for a total transaction of $74,691.20. Following the completion of the sale, the vice president now directly owns 12,774 shares of the company’s stock, valued at $2,806,192.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Srikant M. Datar sold 600 shares of the stock in a transaction that occurred on Wednesday, November 2nd. The shares were sold at an average price of $216.71, for a total value of $130,026.00. Following the sale, the director now directly owns 5,161 shares of the company’s stock, valued at $1,118,440.31. The disclosure for this sale can be found here. Insiders have sold 1,240 shares of company stock worth $268,425 over the last 90 days. 6.70% of the stock is currently owned by corporate insiders.

Stryker Profile

(Get Rating)

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies.

Read More

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYKGet Rating).

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.